Pending talks with regulators, Satellos Bioscience Inc. may seek accelerated approval in Duchenne muscular dystrophy (DMD) for SAT-3247, which yielded positive results in the adult phase II Trailhead study. Shares of Toronto-based Satellos (NASDAQ:MSLE) closed July 8 at $8.98, up 77 cents, or 9.4%, after the firm made public six-month interim data from Trailhead.